<DOC>
	<DOCNO>NCT00731016</DOCNO>
	<brief_summary>We suggest treat Hutchinson-Gilford Progeria Syndrome two molecule ( zoledronic acid pravastatin ) .The therapeutic approach propose objective reduce , prevent delay grave infringement disease , prolong life child , general way , aim improve living condition .</brief_summary>
	<brief_title>Treatment Hutchinson-Gilford Progeria Syndrome With Combination Pravastatin Zoledronic Acid</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Progeria</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Molecularly characterised patient know mutation LMNA gene lead production farnesylated prelamin A , whether truncated Patients must able travel consult Marseille , France necessary exploration plan inclusion step , follow protocol flow chart zoledronic acid injection followup visit Patient old 3 year Patients affiliate beneficiary legal medical insurance Adult patient certify properly inform protocol , sign write consent form . Children and/or disable patient whose parents/legal tutor inform sign write consent form Known hypersensitivity pravastatin zoledronic acid Seric transaminase level higher 3 time normal value CPK level high 5 time normal value Creatininemia high 0.5mg/dl 44mM , creatinin clearance lower 70ml/min/1.73m3 Presence dental trouble , recent dental trouble Maxillary osteonecrosis bone nakedness antecedent Congenital galacosemia , glucose galactose maladsorption syndrome , lactase deficiency Every pathology think incompatible propose treatment investigator Under treatment interfere pravastatin and/or zoledronate metabolism</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>